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Background. In order to support the economic and financial sustainability of the Italian health 
system, there is a need to define technically and economically efficient strategies that assure the 
self-sufficient apheretic production of plasma. 
Material and methods. Process and product costs at the Casa del Donatore (CD) in Bologna were 
determined on the basis of costing models used at Verona's Inter-hospital Department of Transfusional 
Medicine (IDTM) by  academics from the University of Turin and those used at the Marche Regional 
IDTM by academics from Marche Polytechnic University. During the first phase, data was collected 
concerning donors, biological screening tests, the number of units produced/discarded, the materials 
used (individual pharmacy codes and related final expenditure), human resources (number, professional 
status, time involved, the number of activities per day, percentage productivity), equipment, and 
general costs. During the second phase, direct costs were verified and the costs common to the units 
produced were attributed using the functional principle.
Results: The overall cost of a litre of plasma collected by means of apherisis (about € 280) was 
similar at the three centres, but there were differences in their cost structures that could be attributed 
to organisational choices, economic factors and/or structural variables. Plasmapheresis accounts for 
24% of the plasma collected in Marche and the CD, but 17% of that collected in Verona, whereas 
the donation index is lower in the CD (1.8) than in the other two centres (2.2). The annual donor 
screening tests are substantially similar, but there are some differences in their timing (at the time of 
screening candidate donors or at the time of first donation). There are also some differences in the 
use of tests that are not required by law but are carried out in order to protect donors and recipients. 
The working times in three centres are similar, but personnel costs vary because of their different 
retribution policies. 
Discussion. Comparing the cost determinants at each centre made it possible to highlight changes 
that each can make in order to improve efficiency, and may lay the basis for doing the same in other 
organisational contexts.
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Introduction
In order to support the economic and financial 
sustainability of the Italian health system, there is a 
need to define technically and economically efficient 
strategies that assure the self-sufficient apheretic 
production of plasma. Furthermore, the use of such 
collection and production standards could be extended 
throughout the transfusion system.
The aim of this analysis was to compare the strategies 
used at three Italian plasma collection centres of 
excellence and the related production costs in an attempt 
to find a common front of efficiency.
Material and methods
Two research teams from the University of Turin and 
Marche Polytechnic University independently developed 
two models for analysing the cost of collecting plasma 
by means of apheresis:
- a cost accounting model based on an empirical 
analysis of the 12 operating units belonging to the 
Marche Regional IDTM 1;
- a cost analysis based on a simulation model that 
integrates observational data provided by the  IDTM 
in Verona2.
The synergistic convergence of these two experiences 
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led to the creation of a combined model for determining 
process and product costs that was first applied to the 
CD in Bologna3, and subsequently used to re-analyse the 
other two centres in order to update the data and compare 
specific aspects. Figure 1 shows the study design.
Results
Table I and  Figure 2 show the flow of donors and the 
distribution of the donations. Plasmapheresis accounts 
for 24% of the plasma collected in the Marche region 
and at the CD, and 17% of that collected in Verona 
(p<0.001); the donation index at the CD (1.8) is lower 
than in the other two centres (both 2.2; p<0.001).
There are also differences in donor testing at the 
three centres (Table II):
- they use the same tests but there are differences in 
whether they are used at the time of screen or at the 
time of the first donation;
- there are also some differences in the use of tests that 
are not required by law but are carried out in order 
to protect donors and recipients.








Total donations 31,728 66,532 103,083
WB 23,899 53,560 74,954
PA 7,520 11,397 24,078
PPA 309 1,381 2,041
Plasma per donation (mL)
WB (plasma yield) 270 268 266
PA (mean volume) 598 600 525
PPA (plasma yield) 398 400 398
Total active donors 17,474 30,246 45,922
Subject to annual controls 15,217 26,000 NA
Making first donation 1,282 3,606 4,924
Candidate donors 2,097 5,797 9,169
Donors recalled for control NA 3,100 NA
WB: whole blood; PA: plasmapheresis; PPA: plasma platelet apheresis; 
NA: not available.
Figure 1 - Study design.
Figure 2 - Collection and donation index mix in the three centres.
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Table II - Tests in 2013 (significant differences highlighted in grey).
 Bologna CD Verona IDTM Marche Regional IDTM
Immunohematology
ABO (direct and indirect) and Rh D CD/FD CD/FD CD/FD
ABO group control (direct test) and Rh D ALL RD/FD/CD RD/FD
Kell antigens CD/FD CD/FD CD/FD
Direct Coombs test    
Determination of complete Rh phenotype CD/FD CD/FD CD/FD
Serovirology and molecular biology
HBs Ag ALL ALL ALL
HCV Ab ALL ALL ALL
HCV RNA ALL ALL ALL
HBV DNA ALL ALL ALL
HIV-1 RNA ALL ALL ALL
Syphilis serodiagnosis ALL ALL ALL
HIV 1-2 Ab ALL ALL ALL
ALT determination ALL ALL ALL
Routine tests per donation
Complete hemochromocytometry ALL ALL ALL
PT and aPTT - PLASMA AC NO AC
PT and aPTT - PLT RD/AC ANNUAL1 AC
Search for anomalous anti-erythrocytic antibodies CD/AC CD/FD2 CD/AC3
Creatininemia CD/AC FD/AC CD/AC
Glycemia CD/AC FD/AC CD/AC
Proteinemia and serum protein electrophoresis FD/AC FD/AC CD/AC
Cholesterolemia FD/AC FD/AC CD/AC
Triglyceridemia FD/AC FD/AC CD/AC
Ferritinemia FD/AC FD/AC CD/AC/IID
Anti-HBc   ALL
Anti-HBs   Upon request
AST (when ALT altered) FD DD DD
Azotemia CD/AC FD/AC CD/AC
Total and fractionated bilirubin FD  CD/CA
HDL cholesterol   DD
Gamma GT (when ALT altered) FD  DD
Sideremia FD/AC FD/AC DD
Hemoglobin electrophoresis   DD
Ericemia FD/AC  DD
ESR  FD/AC CD/AC
Urine test FD/AC  CD/AC
ECG (at time of first donation and then every two years) FD CD/RD4 RD5
Sodium potassium chlorine FD  DD
Alkaline phosphatase FD  DD
Calcium FD  CD/AC
Fibrinogen AC  DD
RD: regular donor; CD: candidate donor; FD: first donation; AC: annual control; DD: diagnostic detail.1platelet donors; 2also in the case of an immunising 
event; 3if Coombs' test  positive; 4 only when indicated; 4<45 years: once every two years; 5>45 years: every year.
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Figure 3 - Personnel involved in annual plasma collection in the three centres.
Figure 4 - Cost of a litre of plasma collected by means of apheresis in the three centres.
The three centres are absolutely similar in terms of 
the composition of their personnel (p=0.65, Figure 3) 
and working times, but there are differences in personnel 
costs due to differences in retribution policies (data not 
shown). 
The composition of the cost of a litre of plasma 
obtained by means of apheresis is not the same in the 
three centres (p<0.001, Figure 4): the weight of material 
costs is least at the CD (38%), whereas that of personnel 
costs is least at the IDTM in Verona (24%).
Discussion
The differences in the individual cost items are 
attributable to organisational choices, economic factors 
and/or structural variables: for example, the cost of a bag 
for collecting whole blood varies from € 8.70 to € 13.80 
(a difference due to differences in the characteristics of 
the device used, and therefore in their purchase price), 
and the cost of a plasmapheresis kit ranges from € 21.17 
to € 35.60 (due to differences in the number of cell 
separators included in the centralised call for tenders). 
However, the estimated final cost is similar (Table III): 
€ 278 at the Marche Regional IDTM; € 280 at the CD 
in Bologna, both of which are in line with results of the 
model developed for the IDTM in Verona (€ 284, 95% 
CI 251-329).
Conclusions
Given the differences in their cost determinants, 
the comparison made it possible to draw attention to 
the modifications that could be made at each centre in 
order to establish a common threshold of efficiency, 
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Table III - Annual activities in the three centres (€).
 Bologna CD       Verona IDTM* Marche Regional IDTM**
Material costs 60.21  82.47 75.36
Per donation 49.31 54.47 71.56
Per donor test 10.90 28.01 3.81
Personnel costs 71.73 40.57 47.25
Collection 66.56 35.07 39.46
Production 4.60 1.55 7.07
Laboratory tests 0.47 1.74 0.21
Assigned to industry 0.09 1.72 0.51
Associative reimbursement 25.03 26.29 24.04 
Indemnities 1.85 2.52 3.11 
General expenses 8.10 18.46 10.25 
AD of structural resources 0.05  1.93 
Medical Manager 2.08  0.75 
Other 5.96  7.56 
Total per donation 166.91 170.32 160.02
Plasma yield per bag (mL) 596,00 600,00 575,00
Total cost per litre of plasma 280,00 284 ,00
(95% CI: 251-329)
278,00
*Figures from Eandi M, Gandini G, Povero M, Zaniolo O, Pradelli L, Aprili G. Industrial plasma: cost analysis from the third payer 
perspective. Blood Transfus 2015; 13: 37-45 DOI 10.2450/2014.0066-14. **Calculated using a pooled model but in phase of consolidation 
(awaiting balance sheet closure) AD: annual depreciation.
but the model could also be easily applied in other 
organisational contexts.
The analysis revealed the following key points:
- The flow of donors/donations was comparable in 
three centres albeit with main differences in the 
percentage of plasmapheresis (24% in Marche and 
the CD vs 17% in Verona) and the index of donation 
(2.2 in Marche and Verona vs 1.8 in the CD).
- Test profiles: 
 - similarity in annual controls, and serovirology 
and molecular biology tests; 
 - similarity in the testing of "new" donors, albeit 
with differences in the timing of the various tests 
(at the time of screening candidate donors or at 
the time of the first donation); 
 - differences in the use of tests of donations that are 
not required by law but are carried out in order 
to protect donors and recipients. 
- The working times recorded/estimated at the three 
centres were similar, whereas personnel costs 
were different because of differences in retribution 
policies. 
- The differences in the individual cost items seem to 
be attributable to organisational choices, economic 
factors and/or structural variables. 
- The final cost of a unit of plasma is similar: € 280 at 
the CD with slight differences at the other centres.
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